View Exam | PowerPak

1. Which of the following molecules block BOTH vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2)?

A. Ranibizumab B. Aflibercept C. Bevacizumab D. Faricimab E. Unsure

2. Which of the following is NOT a risk associated with intravitreal injections?

A. Endophthalmitis (infection) B. Cataract C. Retinal detachment D. Elevated intraocular pressure (IOP) E. Discoloration of the sclera F. Unsure

3. The leading cause of permanent vision loss in older adults (>65 years of age) in the United States (US) is:

A. Cataract B. Glaucoma C. Age-related macular degeneration (AMD) D. Diabetic retinopathy E. Unsure

4. The leading cause of blindness in diabetic patients is:

A. Cataract B. Diabetic macular edema (DME) C. Proliferative diabetic retinopathy D. Neovascular glaucoma E. Unsure

5. The most effective therapy for DME is:

A. Focal laser therapy B. Intravitreal steroid injections C. Anti-VEGF therapy D. Blood glucose control E. Unsure

6. Sources of data for Real-World Data (RWD) may include all the following EXCEPT:

A. Anecdotal reports B. Claims and billing data C. Electronic health record (EHR) D. Clinical registries E. Digital health data F. Unsure

7. To improve outcomes in patients being treated for AME or DME, all of the following patient education and compliance improvement items should be considered EXCEPT:

A. Explain therapy requirements (ie, frequent visits), cost, and possible adverse effects B. Monitor therapy safety and efficacy C. Describe expectations of therapy D. Shorten the time interval between injections E. Discuss vision improvement expectations F. Unsure

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following molecules block BOTH vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2)?

2. Which of the following is NOT a risk associated with intravitreal injections?

3. The leading cause of permanent vision loss in older adults (>65 years of age) in the United States (US) is:

4. The leading cause of blindness in diabetic patients is:

5. The most effective therapy for DME is:

6. Sources of data for Real-World Data (RWD) may include all the following EXCEPT:

7. To improve outcomes in patients being treated for AME or DME, all of the following patient education and compliance improvement items should be considered EXCEPT:

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following molecules block BOTH vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2)?

2. Which of the following is NOT a risk associated with intravitreal injections?

3. The leading cause of permanent vision loss in older adults (>65 years of age) in the United States (US) is:

4. The leading cause of blindness in diabetic patients is:

5. The most effective therapy for DME is:

6. Sources of data for Real-World Data (RWD) may include all the following EXCEPT:

7. To improve outcomes in patients being treated for AME or DME, all of the following patient education and compliance improvement items should be considered EXCEPT:

« Return to Activity

Customers who Purchased
this Activity also Purchased